NADH vs NADPH

NADH (nicotinamide adenine dinucleotide, reduced form) and NADPH (nicotinamide adenine dinucleotide phosphate, reduced form) are structurally similar dinucleotide cofactors that serve fundamentally different biological roles. NADH is the primary electron carrier for catabolic energy production in mitochondria, while NADPH provides reducing equivalents for anabolic biosynthesis and antioxidant defense. Despite sharing an identical nicotinamide ring that accepts and donates hydride ions, their cellular localization, enzyme specificities, and metabolic contexts diverge dramatically.

Chemical Identity

NADH

Full name: β-Nicotinamide adenine dinucleotide, reduced form
Molecular formula: C₂₁H₂₉N₇O₁₄P₂
Molecular weight: 663.43 Da
Structure: Two nucleotides joined through their phosphate groups — one containing adenine, the other nicotinamide
Redox center: Nicotinamide ring (accepts 2 electrons + 1 proton as hydride ion)
Standard reduction potential: −320 mV (at pH 7.0)
Charge: −2 at physiological pH

NADPH

Full name: β-Nicotinamide adenine dinucleotide phosphate, reduced form
Molecular formula: C₂₁H₃₀N₇O₁₇P₃
Molecular weight: 745.41 Da
Structure: Identical to NADH with an additional 2′-phosphate group on the adenosine ribose
Redox center: Nicotinamide ring (identical to NADH)
Standard reduction potential: −324 mV (at pH 7.0)
Charge: −4 at physiological pH

The single additional phosphate group on NADPH is the only structural difference, yet it is sufficient to create enzyme specificity that separates catabolic from anabolic metabolism.

Property	NADH	NADPH
Molecular weight	663.43 Da	745.41 Da
Phosphate groups	2	3
Standard reduction potential	−320 mV	−324 mV
Primary role	Energy metabolism	Biosynthesis + antioxidant
Cellular compartment	Primarily mitochondria	Primarily cytoplasm
NADP⁺/NADPH ratio	Low (~0.01)	High (~100)

Biological Roles

NADH: Catabolic Electron Carrier

NADH is the primary electron donor to the mitochondrial electron transport chain (ETC):

Glycolysis: NAD⁺ reduced to NADH in the glyceraldehyde-3-phosphate dehydrogenase step (cytoplasm)
Pyruvate dehydrogenase: NAD⁺ → NADH during pyruvate oxidation (mitochondrial matrix)
TCA cycle: 3 NADH produced per acetyl-CoA at isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, and malate dehydrogenase
β-oxidation: NADH generated at 3-hydroxyacyl-CoA dehydrogenase step
ETC Complex I: NADH donates electrons to NADH:ubiquinone oxidoreductase → proton pumping → ATP synthesis

Each NADH yields approximately 2.5 ATP through oxidative phosphorylation (P/O ratio ~2.5).

NADPH: Anabolic Reductant and Antioxidant

NADPH provides reducing equivalents for biosynthetic and protective reactions:

Fatty acid synthesis: NADPH consumed by fatty acid synthase (FAS) — 14 NADPH per palmitate
Cholesterol synthesis: HMG-CoA reductase pathway requires 18 NADPH per cholesterol
Nucleotide synthesis: Ribonucleotide reductase uses NADPH to reduce ribonucleotides to deoxyribonucleotides
P450 monooxygenases: CYP3A4, CYP2D6, and other xenobiotic-metabolizing enzymes use NADPH
Glutathione reduction: Glutathione reductase uses NADPH to maintain reduced glutathione (GSH)
Nitric oxide synthesis: eNOS and nNOS require NADPH as electron donor
Reductive biosynthesis: Collagen hydroxylation, steroidogenesis, and heme synthesis

Functional Divergence

Function	NADH	NADPH
Electron transport chain	Primary donor	Not used
Fatty acid synthesis	Not used	Primary donor
Cholesterol synthesis	Not used	Required
Glutathione reduction	Not used	Required
P450 metabolism	Not used	Required
Glycolysis	Produced	Not involved
TCA cycle	Produced	Not involved
ATP production	~2.5 ATP per NADH	Not directly involved

Cellular NAD(P)⁺/NAD(P)H Ratios

The cell maintains vastly different redox states for NAD and NADPH pools:

NAD⁺/NADH Ratio

Cytosol: ~700:1 (NAD⁺:NADH)
Mitochondrial matrix: ~7:1
Purpose: High NAD⁺/NADH ratio ensures glycolysis and TCA cycle proceed in forward (oxidative) direction
Half-life of turnover: Seconds (rapid cycling)

NADP⁺/NADPH Ratio

Cytosol: ~0.01:1 (NADP⁺:NADPH) — heavily reduced
Purpose: Maintains NADPH in reduced form for immediate use by reductive biosynthetic enzymes
Glutathione defense: High NADPH drives glutathione reductase to keep GSH levels high
Half-life of turnover: Minutes (slower cycling)

The inverted ratios ensure that NADH donates electrons to the ETC (thermodynamically favorable) while NADPH donates electrons to reductive biosynthesis (thermodynamically favorable).

Regeneration Pathways

NADH Regeneration

Malate-aspartate shuttle: Transfers mitochondrial NADH equivalents to cytoplasmic NAD⁺ → 2.5 ATP
Glycerol-3-phosphate shuttle: Transfers NADH electrons to FAD in mitochondria → 1.5 ATP
Lactate dehydrogenase: Regenerates NAD⁺ from NADH using pyruvate (anaerobic glycolysis)
Alcohol dehydrogenase: Regenerates NAD⁺ from NADH during ethanol metabolism
Aldehyde dehydrogenase: Regenerates NAD⁺ during acetaldehyde oxidation

NADPH Regeneration

Pentose phosphate pathway (PPP): Primary source — glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase generate 2 NADPH per glucose-6-phosphate
Malic enzyme: Converts malate to pyruvate + CO₂ + NADPH (cytoplasmic)
Isocitrate dehydrogenase 1 (IDH1): Cytoplasmic isoform generates NADPH
NADP⁺-dependent isocitrate dehydrogenase: Mitochondrial isoform
Folate metabolism: Methylene tetrahydrofolate dehydrogenase generates NADPH

Key Difference

NADH regeneration is tightly coupled to ATP production (oxidative phosphorylation), while NADPH regeneration is coupled to biosynthetic demand and antioxidant defense. G6PD deficiency (favism) illustrates this: impaired NADPH production leads to inability to maintain glutathione, causing oxidative damage to red blood cells.

Supplementation Considerations

NADH Supplementation

Oral bioavailability: Limited — NADH is degraded in GI tract; sublingual formulations may improve absorption
IV NADH: Used in some clinical contexts for mitochondrial support
Cellular entry: NADH does not readily cross cell membranes; must be generated intracellularly
Stability: Susceptible to oxidation; requires careful storage
Clinical evidence: Limited RCTs; some evidence for chronic fatigue and mitochondrial disorders
Dosing: 10-50 mg/day (oral), 250-750 mg IV in some protocols

NADPH Supplementation

Oral bioavailability: Very poor — NADPH does not cross cell membranes
Cellular entry: Requires intracellular regeneration (PPP, malic enzyme)
Stability: Extremely labile; reduces spontaneously in solution
Clinical use: Not clinically supplemented; the cell generates NADPH on demand
Alternative approach: NAD⁺/NADH precursors (NMN, NR) can increase cellular NAD⁺ pool, which indirectly supports NADPH via transhydrogenase

Supplementation Summary

Parameter	NADH	NADPH
Oral bioavailability	Low	Very low
Sublingual bioavailability	Moderate	Very low
IV availability	Yes (clinical)	No (research only)
Intracellular regeneration	Shuttle systems	PPP, malic enzyme
Clinical evidence	Limited	None (supplementation)
Primary supplementation strategy	NMN, NR (NAD⁺ precursors)	Treat G6PD deficiency

Enzyme Specificity

The structural difference (2′-phosphate) creates strict enzyme specificity:

NAD⁺-Specific Enzymes

Lactate dehydrogenase (LDH)
Alcohol dehydrogenase (ADH)
Malate dehydrogenase (MDH)
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Isocitrate dehydrogenase 2 (IDH2, mitochondrial)
α-Ketoglutarate dehydrogenase

NADP⁺-Specific Enzymes

Glucose-6-phosphate dehydrogenase (G6PD)
6-Phosphogluconate dehydrogenase
Malic enzyme (ME1)
Isocitrate dehydrogenase 1 (IDH1, cytoplasmic)
Glutathione reductase (GSR)
Thioredoxin reductase
Nitric oxide synthase (NOS)

Dual-Specificity Enzymes

Some enzymes can use either cofactor, but with vastly different Km values:

Aldehyde dehydrogenase: prefers NAD⁺ (Km ~0.02 mM) over NADP⁺ (Km ~3 mM)
Xanthine dehydrogenase: can use NAD⁺ or NADP⁺

Clinical Relevance

G6PD Deficiency

G6PD deficiency impairs NADPH regeneration, leading to:

Inability to maintain glutathione in reduced state
Oxidative damage to red blood cells
Hemolytic anemia triggered by oxidative stress (drugs, infections, fava beans)
Prevalence: ~400 million people worldwide (most common enzyme deficiency)

Cancer Metabolism

Cancer cells upregulate PPP to increase NADPH production:

NADPH supports reductive biosynthesis for membrane lipid production
NADPH maintains glutathione to combat oxidative stress
G6PD overexpression is observed in many tumor types
IDH1/2 mutations produce 2-hydroxyglutarate (oncometabolite)

Mitochondrial Disorders

Impaired NADH oxidation due to ETC dysfunction:

Complex I deficiency: Reduced NADH oxidation → energy failure
Symptoms: Lactic acidosis, muscle weakness, neurodegeneration
Treatment: CoQ10, riboflavin, carnitine (support ETC function)

References

Nikiforov A, et al. “A metabolic pathway for NAD degradation.” Cell 2011;147:565-576.
Ying W. “NAD⁺ and NADH in cellular functions and cell death.” Front Biosci 2006;11:3129-3148.
Pollak N, et al. “The power of hydrogen peroxide: NADH oxidase from Enterococcus faecalis.” J Biol Chem 2007;282:28594-28600.
Stein LR, Imai S. “The dynamic regulation of NAD metabolism in mitochondria.” Trends Endocrinol Metab 2012;23:502-509.
Belenky P, et al. “NAD⁺ metabolism in health and disease.” Trends Biochem Sci 2007;32:12-19.